Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.

Publication ,  Journal Article
Criscione, LG; St Clair, EW
Published in: Curr Opin Rheumatol
May 2002

Tumor necrosis factor-alpha (TNF-alpha) antagonists have rapidly emerged as a valuable class of antirheumatic agents. Etanercept, a dimerized version of the soluble tumor necrosis factor receptor II, and infliximab, a chimeric anti-TNF-alpha monoclonal antibody, are currently approved for the treatment of rheumatoid arthritis (RA) based on their proven beneficial effects in clinical trials. New insights into the role of TNF-alpha in disease pathogenesis have expanded our understanding about the possible mechanisms by which these agents reduce synovial inflammation and inhibit bone and cartilage degradation. The enlarging safety experience has revealed growing concerns about TNF-alpha inhibition and increased risk for opportunistic infection, most notably the reactivation of latent Mycobacterium tuberculosis infection. Recent recommendations have addressed this risk by calling for pretreatment screening for previous exposure to tuberculosis. The success of etanercept and infliximab therapy for RA has prompted the development of other TNF-alpha antagonists and extended the investigation of this therapeutic approach to other inflammatory diseases. TNF-alpha antagonists promise to shape the care of RA and other rheumatic diseases for many years to come.

Duke Scholars

Published In

Curr Opin Rheumatol

DOI

ISSN

1040-8711

Publication Date

May 2002

Volume

14

Issue

3

Start / End Page

204 / 211

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Tuberculosis
  • Safety
  • Rheumatic Diseases
  • Mycobacterium tuberculosis
  • Humans
  • Arthritis & Rheumatology
  • Antirheumatic Agents
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Criscione, L. G., & St Clair, E. W. (2002). Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol, 14(3), 204–211. https://doi.org/10.1097/00002281-200205000-00002
Criscione, Lisa G., and E William St Clair. “Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.Curr Opin Rheumatol 14, no. 3 (May 2002): 204–11. https://doi.org/10.1097/00002281-200205000-00002.
Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002 May;14(3):204–11.
Criscione, Lisa G., and E. William St Clair. “Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.Curr Opin Rheumatol, vol. 14, no. 3, May 2002, pp. 204–11. Pubmed, doi:10.1097/00002281-200205000-00002.
Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002 May;14(3):204–211.

Published In

Curr Opin Rheumatol

DOI

ISSN

1040-8711

Publication Date

May 2002

Volume

14

Issue

3

Start / End Page

204 / 211

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Tuberculosis
  • Safety
  • Rheumatic Diseases
  • Mycobacterium tuberculosis
  • Humans
  • Arthritis & Rheumatology
  • Antirheumatic Agents
  • 3202 Clinical sciences
  • 1103 Clinical Sciences